Technical Analysis for MDNA - Medicenna Therapeutics Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | -0.67% | |
| Wide Bands | Range Expansion | -0.67% | |
| Oversold Stochastic | Weakness | -0.67% | |
| Calm After Storm | Range Contraction | -8.02% | |
| NR7 | Range Contraction | -8.02% | |
| NR7-2 | Range Contraction | -8.02% |
| Alert | Time |
|---|---|
| Down 5% | about 5 hours ago |
| Up 5% | about 5 hours ago |
| Fell Below Previous Day's Low | about 7 hours ago |
| Down 3% | about 7 hours ago |
| Down 2% | about 7 hours ago |
Get a Trading Assistant
- Earnings date: 2024-11-12
Medicenna Therapeutics Corp. Description
Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinic Drug Cancer Medical Specialties Oncology Clinical Trial Clinical Medicine Cancers Tumor Immunotherapy Treatment Of Cancer Cancer Immunotherapy Stem Cells Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.98 |
| 52 Week Low | 0.38 |
| Average Volume | 85,007 |
| 200-Day Moving Average | 1.955 |
| 50-Day Moving Average | 2.077 |
| 20-Day Moving Average | 2.043 |
| 10-Day Moving Average | 1.711 |
| Average True Range | 0.195 |
| RSI (14) | 31.97 |
| ADX | 27.99 |
| +DI | 13.122 |
| -DI | 37.644 |
| Chandelier Exit (Long, 3 ATRs) | 2.034 |
| Chandelier Exit (Short, 3 ATRs) | 1.856 |
| Upper Bollinger Bands | 2.795 |
| Lower Bollinger Band | 1.290 |
| Percent B (%b) | 0.13 |
| BandWidth | 73.645 |
| MACD Line | -0.189 |
| MACD Signal Line | -0.111 |
| MACD Histogram | -0.0783 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.745 | ||||
| Resistance 3 (R3) | 1.747 | 1.663 | 1.703 | ||
| Resistance 2 (R2) | 1.663 | 1.598 | 1.663 | 1.688 | |
| Resistance 1 (R1) | 1.577 | 1.558 | 1.535 | 1.575 | 1.674 |
| Pivot Point | 1.493 | 1.493 | 1.473 | 1.493 | 1.493 |
| Support 1 (S1) | 1.407 | 1.428 | 1.365 | 1.405 | 1.306 |
| Support 2 (S2) | 1.323 | 1.388 | 1.323 | 1.292 | |
| Support 3 (S3) | 1.237 | 1.323 | 1.278 | ||
| Support 4 (S4) | 1.235 |
